Euthymics' Sweet Dreams Could Be Realized With $24MM Series A
This article was originally published in The Pink Sheet Daily
The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.
You may also be interested in...
As VC Investments Rebound In Q2, Skepticism Lingers
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track
Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.